EX-10.13
Published on April 30, 2026
EXHIBIT 10.13
Employment Agreement
THIS EMPLOYMENT AGREEMENT (the “Agreement”) is entered into by and between Erik Atkisson (the “Employee”) and Achieve Life Sciences, Inc., a Washington corporation (the “Employer” or the “Company”) as of October 20, 2025 (the “Effective Date”).
For the term of this Agreement (“Employment”), the Employer agrees to employ the Employee in the position of Chief Legal Officer. The Employee shall report directly to Richard Stewart, Chief Executive Officer of the Company. The Employee shall have such duties, authority and responsibilities that are commensurate with his being an executive officer of the Employer. During your employment, Employee will perform his duties faithfully and to the best of his ability and will devote his full business efforts and time to the Employer. For the duration of the Employee’s Employment term, Employee agrees not to actively engage in any other employment, occupation or consulting activity for any direct or indirect remuneration without the prior written approval, such approval not to be unreasonably withheld, provided that such activities do not materially adversely affect Employee’s ability to perform and discharge his duties to the Employer or competes with the Company.
1
The Employee will be eligible for paid vacation in accordance with the Employer’s vacation policy. Under the Employer’s current vacation policy, the Employee is eligible for twenty-five (25) days per year of paid vacation.
During your Employment, the Employee shall be authorized to incur necessary and reasonable travel, entertainment and other business expenses in connection with his duties hereunder. The Employer shall promptly reimburse the Employee for such expenses upon presentation of appropriate supporting documentation, all in accordance with the Employer’s generally applicable policies.
2
3
(3) to a continuing or surviving entity described in subsection (i) in connection with a merger, consolidation or corporate reorganization which does not result in a Change in Control under subsection (i));
For purposes of this Section 6(f), a transaction shall not constitute a Change in Control if its sole purpose is to change the state of the Company’s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company’s securities immediately before such transactions.
4
The foregoing is an exclusive list of the acts or omissions that shall be considered “Cause” for the termination of the Employee’s Employment by the Employer. With respect to the acts or omissions set forth in clauses (i), (iii), (iv) and (v) above, (x) the Chief Commercial Officer or Chief Financial Officer (or other representative of the Company) shall provide the Employee with one (1) month advance written notice detailing the basis for the termination of Employment for Cause, (y) during the one-month period after the Employee has received such notice, the Employee shall have an opportunity to cure such alleged Cause events before any termination for Cause is finalized and (z) the Employee shall continue to receive the compensation and benefits provided by this Agreement during the one-month cure period. In addition, no act or failure to act of Employee shall be willful or intentional if performed in good faith with the reasonable belief that the action or inaction was in the best interest of the Employer.
5
$1,500 upon issuance of a patent resulting from such initial patent application, provided Employee is named as an inventor in the patent.
6
In the event that the Employer determines that any of the benefits payable under this Agreement would violate Section 409A, then the Employer and the Employee shall, in good faith, agree to implement adjustments needed to comply with Section 409A. Additionally, notwithstanding anything contained in this Agreement to the contrary, if Employee is deemed by the Employer at the time of Employee’s “separation from service” to be a “specified employee,” each within the meaning of Section 409A, any compensation or benefits to which Employee becomes entitled under this Agreement (or any agreement or plan referenced in this Agreement) in connection with such separation that are subject to Section 409A shall not be made or commence until the date which is six (6) months after Employee’s “separation from service” (or, if earlier, Employee’s death). Such deferral shall only be effected to the extent required to avoid adverse tax treatment to Employee, including (without limitation) the additional twenty percent (20%) tax for which Employee would otherwise be liable under Section 409A(a)(1)(B) in the absence of such deferral. Upon the expiration of the applicable deferral period, any compensation or benefits which would have otherwise been paid during that period (whether in a single lump sum or in installments) in the absence of this Section 10 shall be paid to Employee or Employee’s beneficiary in one lump sum. To the extent that any provision of this Agreement is ambiguous as to its exemption or compliance with Section 409A, the provision will be read in such a manner so that such payments hereunder are exempt from Section 409A to the maximum permissible extent, and for any payments where such construction is not tenable, that those payments comply with Section 409A to the maximum permissible extent. To the extent any nonqualified deferred compensation subject to Section 409A payable to Employee hereunder could be paid in one or more taxable years depending upon Employee completing certain employment-related actions (such as resigning after a failure to cure a Good Reason event and/or returning an effective release), then any such payments will commence or occur in the later taxable year to the extent required by Section 409A. Each payment and benefit payable under this Agreement is intended to constitute a separate payment for purposes of Section 1.409A-2(b)(2) of the U.S. Treasury Regulations.
If the Company is required to prepare an accounting restatement due to its material noncompliance, as a result of the Employee’s misconduct, with any financial reporting requirement under United States securities laws, then, and only if Section 304 of the Sarbanes-Oxley Act of 2002, or a successor provision, is then in effect, the Company may require the Employee to reimburse the Employer for (i) any bonus or other incentive-based or equity-based compensation received by the Employee from the Employer during the 12-month period following the first public issuance or filing with the Securities Exchange Commission (whichever first occurs) of the financial documents embodying such financial reporting requirement and (ii) any profits realized from the sale of securities of Company during such 12-month period.
7
ACHIEVE LIFE SCIENCES, INC.
By: /s/Rick Stewart
Name: Richard Stewart
Title: Chief Executive Officer
Signed:
By: /s/Erik Atkisson
Name: Erik Atkisson
8
EXHIBIT A
List of Inventions
None
9